Germany · Delayed Price · Currency is EUR Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of EUR 16.38 million. The enterprise value is 14.61 million.
| Market Cap | 16.38M |
| Enterprise Value | 14.61M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 15.06M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.76% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 9.00% |
| Owned by Institutions (%) | 3.32% |
| Float | 12.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6,318.69 |
| PB Ratio | 5.39 |
| P/TBV Ratio | 5.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.29 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.53 |
| Quick Ratio | 3.19 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -83.11 |
Financial Efficiency
Return on equity (ROE) is -91.34% and return on invested capital (ROIC) is -47.21%.
| Return on Equity (ROE) | -91.34% |
| Return on Assets (ROA) | -32.71% |
| Return on Invested Capital (ROIC) | -47.21% |
| Return on Capital Employed (ROCE) | -72.51% |
| Revenue Per Employee | 100 |
| Profits Per Employee | -106,292 |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Genomtec has paid 236 in taxes.
| Income Tax | 236 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.77% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.77% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 29.05 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of EUR 2,593 and -2.76 million in losses. Loss per share was -0.19.
| Revenue | 2,593 |
| Gross Profit | -1.62M |
| Operating Income | -2.72M |
| Pretax Income | -2.76M |
| Net Income | -2.76M |
| EBITDA | -2.11M |
| EBIT | -2.72M |
| Loss Per Share | -0.19 |
Balance Sheet
The company has 2.33 million in cash and 557,530 in debt, giving a net cash position of 1.77 million.
| Cash & Cash Equivalents | 2.33M |
| Total Debt | 557,530 |
| Net Cash | 1.77M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 3.04M |
| Book Value Per Share | 0.20 |
| Working Capital | 2.00M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -105,024.72% |
| Pretax Margin | -106,570.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.76% |
| Shareholder Yield | -14.76% |
| Earnings Yield | -16.87% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomtec has an Altman Z-Score of 7.59 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.59 |
| Piotroski F-Score | 2 |